Key points:
- Oversubscribed placement commitments to sophisticated and professional investors to raise $24.6 million
- Capital raising fully funds the Company’s clinical programs including the two oncolytic virotherapy candidates and B-cell immunotherapy candidates through key value inflection points
- Both platforms now fully funded through to meaningful proof of concept for corporate partnering discussions
SYDNEY 02 December 2019: The Board of Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company is pleased to announce they have received firm commitments for a capital raising by way of the placement of up to 683 million ordinary shares (with 1 new option for every 3 new shares issued with an exercise price of $0.054 per new option exercisable on or before 30 November 2022) to professional and sophisticated investors and directors of the Company to raise up to $24.6 million (Placement). New shares issued under the Placement will rank equally with existing Imugene shares. The placement was well supported by existing investors and new sophisticated and institutional investors.
Download this document
